Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Manhattan Pharmaceuticals has reported positive clinical results for Hedrin, a novel, non-insecticide product candidate for the treatment of head lice.
Subscribe to our email newsletter
The study findings demonstrate Hedrin’s superior efficacy compared to malathion, a widely used insecticide treatment in both Europe and North America. These results appeared in the November issue of PLoS One, an international, peer-reviewed journal published by the Public Library of Science.
In this randomized, controlled, assessor-blinded, parallel group clinical trial, 73 adult and child subjects with active head lice infestations were treated with Hedrin or malathion liquid. Using intent-to-treat analysis, Hedrin achieved a statistically significant cure rate of 70% compared to 33% with malathion liquid. Using the per-protocol analysis Hedrin achieved a highly statistically significant cure rate of 77% compared to 35% with malathion.
Additionally, Hedrin-treated subjects experienced no irritant reactions, and Hedrin showed clinical equivalence to malathion in its ability to inhibit egg hatching. Overall, investigators and study subjects rated Hedrin as less odorous, easier to apply and easier to wash out. Further, subjects treated with Hedrin stated they were significantly more inclined to use the product again (97%) versus those using malathion (31%).